Guerra Pan Advisors LLC Trims Holdings in AstraZeneca PLC $AZN

Guerra Pan Advisors LLC lessened its stake in AstraZeneca PLC (NASDAQ:AZN) by 18.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,509 shares of the company’s stock after selling 2,137 shares during the period. Guerra Pan Advisors LLC’s holdings in AstraZeneca were worth $664,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Goldman Sachs Group Inc. increased its holdings in shares of AstraZeneca by 30.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after acquiring an additional 3,224,251 shares during the period. Valeo Financial Advisors LLC grew its position in AstraZeneca by 14,797.3% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after purchasing an additional 2,307,047 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of AstraZeneca by 2,389.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock valued at $142,798,000 after acquiring an additional 1,961,764 shares during the period. American Century Companies Inc. increased its holdings in shares of AstraZeneca by 406.9% in the first quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock valued at $148,517,000 after purchasing an additional 1,621,974 shares during the period. Finally, Jennison Associates LLC raised its position in AstraZeneca by 15.2% during the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock worth $850,255,000 after buying an additional 1,605,133 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AZN. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group started coverage on AstraZeneca in a report on Monday, October 27th. They set a “buy” rating for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Trading Up 2.6%

Shares of AZN opened at $91.00 on Friday. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $91.91. The stock has a market cap of $282.23 billion, a price-to-earnings ratio of 34.21, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34. The firm has a 50 day simple moving average of $83.00 and a 200-day simple moving average of $76.79. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The business had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.08 earnings per share. Equities analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.